/PRNewswire/ Novo Holdings, a leading international life sciences investor, today announces that its portfolio company Syndesi Therapeutics ( Syndesi ) has.
NorthSea Therapeutics Initiates Phase 1 Trial of SEFA-6179, Targeting the Orphan Indication Intestinal Failure-Associated Liver Disease morningstar.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from morningstar.com Daily Mail and Mail on Sunday newspapers.
Pre-clinical studies demonstrated beneficial effects of SEFA-6179 in preventing the development of parenteral nutrition-induced cholestasis and liver injury associated with intestinal failure associated
/PRNewswire/ Novo Seeds, the early stage investment and company creation team of Novo Holdings, today publishes its review of 2021 – an outstanding year for.
/PRNewswire/ Novo Seeds, the early stage investment and company creation team of Novo Holdings, today publishes its review of 2021 – an outstanding year for.